미만성 거대 B세포 림프종(DLBCL) 시판 의약품 및 파이프라인 의약품 평가, 임상시험, 경쟁 구도
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
상품코드
:
1354502
리서치사
:
GlobalData
발행일
:
2023년 08월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
2023년 16개국에서 미만성 거대 B세포 림프종(DLBCL) 진단을 받은 유병자 수는 555,000명 이상이 될 것으로 예측됩니다. 리툭시맙과 화학요법의 병용요법은 DLBCL 1차 치료의 표준 치료법이며, DLBCL의 후기 파이프라인에는 5건의 등록 전 약물과 22건의 임상 3상 시험이 진행 중이며, 지난 10년간 1,479건의 임상시험이 진행되었습니다. 파트너십은 북미와 유럽 DLBCL 분야에서 가장 두드러진 거래 형태가 되었습니다.
이 보고서에서는 현재와 미래의 미만성 거대 B세포 림프종(DLBCL) 치료제 경쟁 구도에 대한 데이터 기반 개요를 제공합니다.
목차
제1장 서문
제2장 주요 조사 결과
제3장 질병 개요
제4장 출시 의약품 평가
- 주요 출시 의약품
- 작용기전별 개요
- 투여 경로별 개요
- 출시 의약품 개요와 판매 예측
제5장 가격 결정과 상환 평가
제6장 파이프라인 의약품 평가
- 3상 파이프라인 의약품
- 개발 단계별 개요
- 분자 유형별 개요
- 작용기전별 개요
- 투여 경로별 개요
- 의약품 특이적 상전이 성공률(PTSR)과 승인 가능성(LoA)
- 치료 영역 및 적응증 고유 PTSR 및 LoA
제7장 임상시험 평가
- 역사적 개요
- 단계별 개요
- 현황별 개요
- 진행중 및 계획중인 임상시험 단계별 개요
- 가상 컴포넌트를 사용한 임상시험
- 지리적 개요
- 지역별 단일국 및 다국적 시험
- 주요 20개 스폰서 단계별 내역
- 주요 20개 스폰서 현황별 내역
- 엔드포인트 현황별 개요
- 인종 및 민족별 개요
- 등록 데이터
- 임상시험 사이트 주요 20개국
- 세계의 주요 20개 사이트
- 실현 가능성 분석 - 지리적 개요
- 실현 가능성 분석 - 벤치마크 모델
제8장 거래 상황
- 지역별 합병, 인수, 전략적 제휴
- 최근의 합병, 인수, 전략적 제휴
제9장 상업적 평가
제10장 향후의 시장 성장 촉진요인
제11장 부록
LSH
영문 목차
Abstract
This reports provides a data-driven overview of the current and future competitive landscape in DLBCL therapeutics.
- More than 555,000 diagnosed prevalent cases of DLBCL are anticipated in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for DLBCL.
- Rituximab in combination with chemotherapy is the standard treatment for DLBCL in the first-line setting.
- The late-stage pipeline for DLBCL includes five drugs in pre-registration and 22 drugs in Phase III.
- Clinical trial activity in DLBCL was strong during the past 10 years with 1,479 trials conducted overall.
- Partnership was the most prominent deals type ventured in the DLBCL space across North America and Europe.
Scope
GlobalData's DLBCL: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the DLBCL market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DLBCL market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table of Contents
1 Preface
- 1.1 Contents
- 1.2 Report Scope
- 1.3 List of Tables and Figures
- 1.4 Abbreviations
2 Key Findings
3 Disease Landscape
- 3.1 Disease Overview
- 3.2 Epidemiology Overview
- 3.3 Treatment Overview
4 Marketed Drugs Assessment
- 4.1 Leading Marketed Drugs
- 4.2 Overview by Mechanism of Action
- 4.3 Overview by Route of Administration
- 4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
- 5.1 Annual Therapy Cost
- 5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
- 6.1 Phase III Pipeline Drugs
- 6.2 Overview by Development Stage
- 6.3 Overview by Molecule Type
- 6.4 Overview by Mechanism of Action
- 6.5 Overview by Route of Administration
- 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
- 6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
- 7.1 Historical Overview
- 7.2 Overview by Phase
- 7.3 Overview by Status
- 7.4 Overview by Phase for Ongoing and Planned Trials
- 7.5 Trials with Virtual Components
- 7.6 Geographic Overview
- 7.7 Single-Country and Multinational Trials by Region
- 7.8 Top 20 Sponsors with Breakdown by Phase
- 7.9 Top 20 Sponsors with Breakdown by Status
- 7.10 Overview by Endpoint Status
- 7.11 Overview by Race and Ethnicity
- 7.12 Enrollment Data
- 7.13 Top 20 countries for Trial Sites
- 7.14 Top 20 Sites Globally
- 7.15 Feasibility Analysis - Geographic Overview
- 7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
- 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
- 8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
10 Future Market Catalysts
11 Appendix
- 11.1 Methodology
- 11.2 Methodology - Sales Forecast
- 11.3 Methodology - Pricing and Reimbursement
- 11.4 Methodology - PTSR and LoA Analysis
- 11.5 About the Authors
- 11.6 Contact Us
- 11.7 Disclaimer
관련자료
